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INTRODUCTION
Gadopentetate dimeglumine (GD: gadolinium complexed
with diethylenetriamine pentaacetic acid [DTPA]) is a mag-
netic resonance (MR) imaging contrast agent in wide clini-
cal use. The intravenous administration of GD is relatively
safe and rarely causes systemic toxicity in the course of rou-
tine imaging studies (1). Although one study (2) demonstrat-
ed the safety and feasibility of` low-dose intrathecal GD for
evaluating obstructions and communications of the various
subarachnoid spaces, spontaneous or traumatic/postsurgical
cerebrospinal fluid (CSF) leaks, subarachnoid space CSF flow,
and parenchymal central nervous system (CNS) interstitial
diffusion dynamics, the general safety of intrathecal GD has
not been established. Moreover, cases of high-dose intrathe-
cal GD administration to humans have rarely been reported.
We report the case of an overdose intrathecal GD injection
presenting with neurotoxic manifestations, including a dec-
reased level of consciousness, global aphasia, rigidity, and visu-
al disturbance.
CASE REPORT
A 42-yr-old male was admitted to our neurosurgical inten-
sive care unit from an outside hospital after the accidental
intrathecal injection of 6 mL of a GD contrast medium (Mag-
nevist
�, Bayer HealthCare Pharmaceuticals, Wayne, NJ, USA),
instead of an iodine-containing contrast medium (Omnipa-
que
�, GE Healthcare, Ireland) during computed tomographic
myelography. The patient had a history of lumbar fusion sur-
gery for spinal canal stenosis and complained of recurrent right
buttock and leg pain that started 1 month before this incident.
The doctor at the outside hospital decided to evaluate the pati-
ent’s symptoms with computed tomographic myelography.
However, the pharmacy accidentally delivered a GD contrast
medium to the doctor, and this medium was given to the
patient intrathecally. Six hours after the injection, the patient
became confused, with global aphasia and vomiting. Brain
computed tomography (CT) images of the patient revealed
diffuse high density throughout the subarachnoid space. 
When the patient was transferred to our hospital, his con-
dition had worsened. He was stuporous, with severe rigidity
and intermittent seizures. He had a blood pressure of 180/90
mmHg, and his body temperature was 40.0℃. During the
neurological examination, he showed global aphasia, severe
rigidity, jerking movements of the left extremities, and neck
stiffness. Babinski's sign and ankle clonus were not noted.
Routine laboratory parameters showed no relevant abnormal-
ities. Brain CT about 10 hr after administering the GD also
showed diffuse high density throughout the subarachnoid
space (Fig. 1). Conventional digital subtraction angiography,
which was performed to rule out a spontaneous subarachnoid
hemorrhage, revealed no definite abnormality (Fig. 2). Over
the following 4 days, the patient gradually became alert. There
were no seizures with anticonvulsants. On day 4 after admis-
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and rarely causes systemic toxicity in the course of routine imaging studies. How-
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global aphasia and rigidity had also disappeared, and no addi-
tional focal neurological deficits were observed, except for
the visual disturbances, which persisted until day 7. On day
15, he was discharged home with no specific symptoms or
complaints.
At a follow-up visit 1 month after discharge, he complained
of recurrent visual disturbances. The ophthalmologic exam-
ination revealed bilateral optic atrophy that did not improve
until the 1-yr follow-up.
DISCUSSION
GD is an MR imaging contrast agent in wide clinical use.
The intravenous application of GD is relatively safe and rarely
causes systemic toxicity in the course of routine imaging stud-
ies (1). Preclinical studies and extensive clinical trials have
established its safety and tolerance when injected via the intra-
venous route for MR imaging enhancement studies. Reports
have revealed some potentially adverse systemic effects, altho-
ugh the incidence of these side effects is low (2, 3). Nausea
or vomiting and headache are the most common side effects,
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Fig. 1. Brain CT images about 10 hr after the administration of GD showing diffuse high density throughout the subarachnoid space. (A)
At the level of basal cisterns and (B) sylvian fissure.
Fig. 2. Conventional digital subtraction angiographies showing no definite vascular abnormality. (A) Right internal carotid artery (ICA), antero-
posterior (AP) view. (B) Left ICA, AP view. (C, D) Left vertebral artery, AP (C) and lateral (D) view.
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Bwith frequencies ranging from 0.26 to 0.42% (2, 4). Other
rare reactions reported after the intravenous administration
of gadolinium products include paresthesias, dizziness, focal
convulsions, urticaria, mucosal reactions, generalised flush-
ing, cardiovascular reactions (e.g., tachycardia, arrhythmia),
generalised seizures, laryngospasm, and anaphylactic shock
(2, 3).
Recently, the intrathecal administration of GD has attract-
ed medical attention due to the possible applications of int-
rathecal gadolinium-enhanced MR myelography/cisternog-
raphy. The possible practical uses of MR imaging include
assessing communication with or obstruction of the CSF path-
ways (e.g., arachnoid cysts and neoplastic subarachnoid space
pathway stenosis/obliteration), the evaluation of CSF flow
dynamics in the subarachnoid space (e.g., communicating
normal-pressure hydrocephalus, postinflammatory cranio-
spinal arachnoid adhesions and loculations), the investigation
of spontaneous or acquired craniospinal CSF fistulae, and pos-
sibly the analysis of CNS parenchymal extracellular space
gadolinium diffusion dynamics in various pathological con-
ditions (e.g., hydrocephalus, encephalomalacia, dementia,
cerebral ischemia, and cerebral neoplasia) (2, 5).
Di Chiro et al. (6) performed the first animal experiment
involving the injection of gadolinium into the subarachnoid
space in 1985. The adverse effects of intraventricular gadolin-
ium injection in animal models included behavioural, neu-
rological (focal seizure activity, ataxia, and delayed tremor),
and histopathological (oligodendroglia loss, astrocyte hyper-
trophy, and eosinophilic granule formation) changes (7, 8).
However, these pathological changes were seen only follow-
ing the intraventricular injection of relatively high doses of
gadolinium; no such behavioural or morphological changes
were reported in the same studies when the total dose of intra-
ventricular gadolinium was less than 15 mL (3.3 mM/g brain)
(7).
Some studies have described the safety of the intrathecal
application of GD for MR myelography or cisternography (2,
5, 9). In these studies, doses of 0.5-1.0 mL Magnevist
� (0.25-
0.5 mM GD) were administered into the subarachnoid space
and were reported to be well tolerated with minor adverse
effects (e.g., headache) and only rare severe, but transient, com-
plications like hemiparesis and gait disturbance (9). 
In our case, the dosage was 6-12 times higher than in those
studies (2, 5, 9), probably explaining the more severe and pro-
longed neurotoxic manifestations including bilateral optic
atrophy. In two published cases, the high-dose administra-
tion of GD produced a fluctuating level of consciousness and
neurological deficits (1, 10). In one case, the total gadolini-
um dose administered intravenously over 7 days was 60-80
mL (1). In the other case, 20 mL of GD were injected via the
intrathecal route by accident (10). They resulted in a sequence
of events that led to an encephalopathy, and suggested a novel
pathological entity: gadolinium encephalopathy (1, 10).
In the recent case report, Li et al. (11) supposed that there
is no CSF-brain barrier with regard to GD, as diffusion of
the GD into the cerebral gray matter was evident on the T1-
weighted and FLAIR images. This is consistent with previ-
ous findings in an animal study (7). Interestingly, GD can
also penetrate into the cerebral deep white matter through
the perivascular spaces (11). This provides evidence in vivo
to support the idea that the perivascular space is a channel
for CSF-brain exchanges.
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Fig. 3. Follow-up brain CT images on day 4 after admission. The diffuse high density throughout the subarachnoid space had disappeared.
(A) At the level of basal cisterns and (B) sylvian fissure.
A BWe performed the conservative managements for this pati-
ent: intravenous hydration, anticonvulsant for seizures and
general supportive care. Li et al. (11) suggested that a prompt
continuous CSF draining through a catheter placed into the
lumbar cisterna could be a life-saving procedure. Glucosteroid
(methylprednisolone) has been used widely in patients with
closed-head injuries or brain tumors to prevent and help re-
verse brain edema (11). The use of methylprednisolone also
could be helpful in our patient regaining consciousness after
the intrathecal GD injection.
In conclusion, we report a very rare case of an overdose in-
trathecal GD injection presenting with neurotoxic manifes-
tations, including a decreased level of consciousness, global
aphasia, rigidity, and visual disturbance. Although the major
limitation of our report is the lack of serial serum and CSF
gadolinium levels, future studies could analyze these indices
and reference levels in human patients to see if the neurologi-
cal complications correlate with the gadolinium levels.
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